Cargando…

Functional Nanomedicines for Targeted Therapy of Bladder Cancer

Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Chao, Liu, Heng, Fan, Yanpeng, He, Jiahao, Li, Fuqiu, Wang, Jin, Hou, Yuchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635105/
https://www.ncbi.nlm.nih.gov/pubmed/34867408
http://dx.doi.org/10.3389/fphar.2021.778973
_version_ 1784608236294373376
author Tang, Chao
Liu, Heng
Fan, Yanpeng
He, Jiahao
Li, Fuqiu
Wang, Jin
Hou, Yuchuan
author_facet Tang, Chao
Liu, Heng
Fan, Yanpeng
He, Jiahao
Li, Fuqiu
Wang, Jin
Hou, Yuchuan
author_sort Tang, Chao
collection PubMed
description Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. However, conventional intravesical chemotherapy lacks selectivity for tumor tissues and the concentration of drug is reduced with the excretion of urine, leading to frequent administration and heavy local irritation symptoms. While nanomedicines can overcome all the above shortcomings and adhere to the surface of bladder tumors for a long time, and continuously and efficiently release drugs to bladder cancers. The rapid advances in targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery to eradicate tumor cells, with reduced side-effects. This review summarizes the different available nano-systems of targeted drug delivery to bladder cancer tissues. The challenges and prospects of targeted therapy for bladder cancer are additionally discussed.
format Online
Article
Text
id pubmed-8635105
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86351052021-12-02 Functional Nanomedicines for Targeted Therapy of Bladder Cancer Tang, Chao Liu, Heng Fan, Yanpeng He, Jiahao Li, Fuqiu Wang, Jin Hou, Yuchuan Front Pharmacol Pharmacology Bladder cancer is one of most common malignant urinary tract tumor types with high incidence worldwide. In general, transurethral resection of non-muscle-invasive bladder cancer followed by intravesical instillation of chemotherapy is the standard treatment approach to minimize recurrence and delay progression of bladder cancer. However, conventional intravesical chemotherapy lacks selectivity for tumor tissues and the concentration of drug is reduced with the excretion of urine, leading to frequent administration and heavy local irritation symptoms. While nanomedicines can overcome all the above shortcomings and adhere to the surface of bladder tumors for a long time, and continuously and efficiently release drugs to bladder cancers. The rapid advances in targeted therapy have led to significant improvements in drug efficacy and precision of targeted drug delivery to eradicate tumor cells, with reduced side-effects. This review summarizes the different available nano-systems of targeted drug delivery to bladder cancer tissues. The challenges and prospects of targeted therapy for bladder cancer are additionally discussed. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8635105/ /pubmed/34867408 http://dx.doi.org/10.3389/fphar.2021.778973 Text en Copyright © 2021 Tang, Liu, Fan, He, Li, Wang and Hou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tang, Chao
Liu, Heng
Fan, Yanpeng
He, Jiahao
Li, Fuqiu
Wang, Jin
Hou, Yuchuan
Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title_full Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title_fullStr Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title_full_unstemmed Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title_short Functional Nanomedicines for Targeted Therapy of Bladder Cancer
title_sort functional nanomedicines for targeted therapy of bladder cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635105/
https://www.ncbi.nlm.nih.gov/pubmed/34867408
http://dx.doi.org/10.3389/fphar.2021.778973
work_keys_str_mv AT tangchao functionalnanomedicinesfortargetedtherapyofbladdercancer
AT liuheng functionalnanomedicinesfortargetedtherapyofbladdercancer
AT fanyanpeng functionalnanomedicinesfortargetedtherapyofbladdercancer
AT hejiahao functionalnanomedicinesfortargetedtherapyofbladdercancer
AT lifuqiu functionalnanomedicinesfortargetedtherapyofbladdercancer
AT wangjin functionalnanomedicinesfortargetedtherapyofbladdercancer
AT houyuchuan functionalnanomedicinesfortargetedtherapyofbladdercancer